<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15105133</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0066-4804</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>5</Issue><PubDate><Year>2004</Year><Month>May</Month></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity.</ArticleTitle><Pagination><StartPage>1766</StartPage><EndPage>1772</EndPage><MedlinePgn>1766-72</MedlinePgn></Pagination><Abstract><AbstractText>Picornaviruses (PV) include human rhinovirus (HRV), the primary cause of the common cold, and the enteroviruses (EV), which cause serious diseases such as poliomyelitis, meningoencephalitis, and systemic neonatal disease. Although no compounds for PV infections have been approved in the United States, pirodavir was one of the most promising capsid-binding compounds to show efficacy in human clinical trials for chemoprophylaxis of the common cold. Susceptibility to hydrolysis precluded its use as an oral agent. We have developed orally bioavailable pyridazinyl oxime ethers that are as potent as pirodavir. Compounds BTA39 and BTA188 inhibited a total of 56 HRV laboratory strains and three clinical isolates as determined by neutral red uptake assay. At concentrations of &lt;100 nM, BTA39 inhibited 69% of the HRV serotypes and isolates evaluated, BTA188 inhibited 75%, and pirodavir inhibited 59% of the serotypes and isolates. The 50% inhibitory concentrations (IC(50)s) for the two compounds ranged from 0.5 nM to 6,701 nM. The compounds also inhibited EV, including coxsackie A and B viruses (IC(50) = 773 to 3,608 nM) and echoviruses (IC(50) = 193 to 5,155 nM). BTA39 only inhibited poliovirus strain WM-1 at 204 nM, and BTA188 only inhibited poliovirus strain Chat at 82 nM. EV 71 was inhibited by BTA39 and BTA188, with IC(50)s of 1 and 82 nM, respectively. Both compounds were relatively nontoxic in actively growing cells (50% cytotoxic doses, &gt;/=4,588 nM). These data suggest that these oxime ethers warrant further investigation as potential agents for treating selected PV infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barnard</LastName><ForeName>D L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logan, Utah 84322-5600, USA. honery@cc.usu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hubbard</LastName><ForeName>V D</ForeName><Initials>VD</Initials></Author><Author ValidYN="Y"><LastName>Smee</LastName><ForeName>D F</ForeName><Initials>DF</Initials></Author><Author ValidYN="Y"><LastName>Sidwell</LastName><ForeName>R W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>K G W</ForeName><Initials>KG</Initials></Author><Author ValidYN="Y"><LastName>Tucker</LastName><ForeName>S P T</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Reece</LastName><ForeName>P A R</ForeName><Initials>PA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010091">Oximes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011724">Pyridazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>261QK3SSBH</RegistryNumber><NameOfSubstance UI="D009499">Neutral Red</NameOfSubstance></Chemical><Chemical><RegistryNumber>BML697718K</RegistryNumber><NameOfSubstance UI="C074589">pirodavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002213" MajorTopicYN="N">Capsid</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003588" MajorTopicYN="N">Cytopathogenic Effect, Viral</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000882" MajorTopicYN="N">Haplorhini</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007624" MajorTopicYN="N">KB Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009499" MajorTopicYN="N">Neutral Red</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010091" MajorTopicYN="N">Oximes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010849" MajorTopicYN="N">Picornaviridae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011724" MajorTopicYN="N">Pyridazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012229" MajorTopicYN="N">Rhinovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2004</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15105133</ArticleId><ArticleId IdType="pmc">PMC400527</ArticleId><ArticleId IdType="doi">10.1128/AAC.48.5.1766-1772.2004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andries, K., B. Dewindt, J. Snoeks, L. Wouters, H. Moereels, P. J. Lewi, and P. A. Janssen. 1990. Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. J. Virol. 64:1117-1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC249225</ArticleId><ArticleId IdType="pubmed">2154596</ArticleId></ArticleIdList></Reference><Reference><Citation>Andries, K., B. Dewindt, J. Snoeks, R. Willebrords, K. van Eemeren, R. Stokbroekx, and P. A. J. Janssen. 1992. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob. Agents Chemother. 36:100-107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189235</ArticleId><ArticleId IdType="pubmed">1317142</ArticleId></ArticleIdList></Reference><Reference><Citation>Andries, K. 1993. Discovery of pirodavir, a broad-spectrum inhibitor of rhinoviruses, p. 179-209. In J. Adams and V. J. Merluzzi (ed.), The search for antiviral drugs. Birkhauser, Boston, Mass.</Citation></Reference><Reference><Citation>Barnard, D. L., V. D. Stowell, K. L. Seley, V. R. Hegde, S. R. Das, V. P. Rajappan, S. W. Schneller, D. F. Smee, and R. W. Sidwell. 2001. Inhibition of measles virus replication by 5&#x2032;-nor carbocyclic adenosine analogues. Antivir. Chem. Chemother. 12:241-250.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771733</ArticleId></ArticleIdList></Reference><Reference><Citation>Couch, R. B. 2001. Rhinoviruses, p. 777-797. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed., vol. 1. Lippincott Williams and Wilkins, Philadelphia, Pa.</Citation></Reference><Reference><Citation>Diana, G. D., and D. C. Pevear. 1997. Antipicornavirus drugs: current status. Antivir. Chem. Chemother. 8:401-408.</Citation></Reference><Reference><Citation>Dragovich, P. S., T. J. Prins, R. Zhou, S. E. Webber, J. T. Marakovits, S. A. Fuhrman, A. K. Patick, D. A. Matthews, C. A. Lee, C. E. Ford, B. J. Burke, P. A. Rejto, T. F. Hendrickson, T. Tuntland, E. L. Brown, J. W. Meador, R. A. Ferre, J. E. V. Harr, and M. B. Kosa. 1999. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P-1 lactam moieties as L-glutamine replacements. J. Med. Chem. 42:1213-1224.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197965</ArticleId></ArticleIdList></Reference><Reference><Citation>Giranda, V. L., and G. D. Diana. 1987. Rhinoviral capsid-binding inhibitors: structural basis for understanding rhinoviral biology and for drug design, p. 487-524. In P. Veerapandian (ed.), Structure-based design. Marcel Dekker, Inc., New York, N.Y.</Citation></Reference><Reference><Citation>Hayden, F. G., G. J. Hipskind, D. H. Woerner, G. F. Eisen, M. Janssens, P. A. J. Janssen, and K. Andries. 1995. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob. Agents Chemother. 39:290-294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC162529</ArticleId><ArticleId IdType="pubmed">7726484</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz, B. A., and L. M. Vance. 1995. The antiviral compound enviroxime targets the 3A-coding region of rhinovirus and poliovirus. J. Virol. 69:4189-4197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189156</ArticleId><ArticleId IdType="pubmed">7769678</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson, J. L., E. Lesho, and C. Peterson. 2000. Zinc and the common cold: a meta-analysis revisited. J. Nutr. 130:1512S-1515S.</Citation><ArticleIdList><ArticleId IdType="pubmed">10801968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser, L., C. E. Crump, and F. G. Hayden. 2000. In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antivir. Res. 47:215-220.</Citation><ArticleIdList><ArticleId IdType="pubmed">10974374</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews, D. A., P. S. Dragovich, S. E. Webber, S. A. Fuhrman, A. K. Patick, L. S. Zalman, T. F. Hendrickson, R. A. Love, T. J. Prins, J. T. Marakovits, R. Zhou, C. E. Ford, J. W. Meador, R. A. Ferre, E. L. Brown, S. L. Binford, M. A. Brothers, and D. M. DeLisle. 1999. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. USA 96:11000-11007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34232</ArticleId><ArticleId IdType="pubmed">10500114</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinlay, M. A., D. C. Pevear, and M. G. Rossmann. 1992. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu. Rev. Microbiol. 46:635-654.</Citation><ArticleIdList><ArticleId IdType="pubmed">1332585</ArticleId></ArticleIdList></Reference><Reference><Citation>Novick, S. G., J. C. Godfrey, N. J. Godfrey, and H. R. Wilder. 1996. How does zinc modify the common cold? Clinical observations and implications regarding mechanisms of action. Med. Hypotheses 46:295-302.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676770</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick, A. K., S. L. Binford, M. A. Brothers, R. L. Jackson, C. E. Ford, M. D. Diem, F. Maldonado, P. S. Dragovich, R. Zhou, T. J. Prins, S. A. Fuhrman, J. W. Meador, L. S. Zalman, and D. A. Matthews. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 43:2444-2450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC89498</ArticleId><ArticleId IdType="pubmed">10508022</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear, D. C., T. M. Tull, M. E. Seipel, and J. M. Groarke. 1999. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 43:2109-2115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC89431</ArticleId><ArticleId IdType="pubmed">10471549</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotbart, H. A. 2002. Treatment of picornavirus infections. Antivir. Res. 53:83-98.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750935</ArticleId></ArticleIdList></Reference><Reference><Citation>Tebbe, M. J., W. A. Spitzer, F. Victor, S. C. Miller, C. C. Lee, T. R. Sattelberg, Sr., E. McKinney, and J. C. Tang. 1997. Antirhino/enteroviral vinylacetylene benzimidazoles: a study of their activity and oral plasma levels in mice. J. Med. Chem. 40:3937-3946.</Citation><ArticleIdList><ArticleId IdType="pubmed">9397174</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson, K. G., R. N. Brown, R. Cameron, D. K. Chalmers, S. Hamilton, B. Jin, G. Y. Krippner, A. Luttick, D. B. McConnell, P. A. Reece, J. Ryan, P. C. Stanislawski, S. P. Tucker, W. Y. Wu, D. L. Barnard, and R. W. Sidwell. 2003. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J. Med. Chem. 46:3181-3184.</Citation><ArticleIdList><ArticleId IdType="pubmed">12852746</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>